Government-Owned Inventions; Availability for Licensing, 12008 [2021-04070]
Download as PDF
<![CDATA[
12008
Federal Register / Vol. 86, No. 38 / Monday, March 1, 2021 / Notices
Competitive Advantages
• This invention addresses an urgent
need to protect against permanent
hearing loss resulting from therapies
with commonly used but ototoxic drugs,
including cisplatin.
• Statins are already extensively used
therapeutically to lower blood
cholesterol and have well understood
drug profiles, making them ideal
candidates for repurposing.
Development Stage: An observational
clinical trial (NCT03225157) in patients
with head and neck cancers has been
completed.
Inventors: Lisa Lynn Cunningham
(NIDCD), Nicole C. Schmitt (NIDCD),
and Katharine Ann Fernandez (NIDCD).
Publications: J Clin Invest.
2021;131(1):e142616.
Intellectual Property: HHS Reference
No. E–029–2020—PCT/US21/14918
filed January 25, 2021; U.S. Patent
Application No. 62/966,794 filed
January 28, 2020.
Licensing Contact: Brian W. Bailey,
Ph.D.; 301–594–4094; bbailey@
mail.nih.gov.
Bruce D. Goldstein,
Director, National Heart, Lung, and Blood
Institute, Office of Technology Transfer and
Development, National Institutes of Health.
[FR Doc. 2021–04069 Filed 2–26–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Heart, Lung, and
Blood Institute (NHLBI), National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of sublicensable
patent licenses to Simon Fraser
University (‘‘Simon Fraser’’), a nonprofit university located in British
Columbia, Canada, and Le Centre
National de la Recherche Scientifique
(‘‘CNRS’’), a public scientific and
technological establishment located in
France, its rights to the inventions and
patents listed in the SUPPLEMENTARY
INFORMATION section of this notice.
DATES: Only written comments and/or
applications for a license which are
received by the NHLBI Office of
Technology Transfer and Development
on or before March 16, 2021 will be
considered.
SUMMARY:
VerDate Sep<11>2014
18:48 Feb 26, 2021
Jkt 253001
Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
exclusive patent license should be
directed to: Brian W. Bailey, Ph.D.,
Senior Technology Transfer Manager,
NHLBI Office of Technology Transfer
and Development, 31 Center Drive, Rm.
4A29, MSC 2479, Bethesda, MD 20892–
2479 (for business mail), Telephone
(301) 594–4094; Email: bbailey@
mail.nih.gov.
ADDRESSES:
The
following and all continuing U.S. and
foreign patents/patent applications
thereof are the intellectual properties to
be licensed under the prospective
agreement to Stanford: United States
Provisional Patent Application No. 62/
489,346 filed April 24, 2017 and
entitled ‘‘FLUORIGEN–BINDING RNA
APTAMERS’’ [HHS Reference No. E–
152–2018/0–US–01].
The patent rights in these inventions
have been assigned to the Government
of the United States of America, Simon
Fraser, and CNRS. The prospective
patent license will be for the purpose of
consolidating the patent rights to CNRS,
one of the co-owners of said rights, for
commercial development, and the
purpose of consolidating the patent
rights to CNRS and Simon Fraser for
marketing. Consolidation of these coowned rights is intended to expedite
development of the invention,
consistent with the goals of the BayhDole Act codified as 35 U.S.C. 200–212.
The prospective patent license will be
worldwide, exclusive, and may be
limited to those fields of use
commensurate in scope with the patent
rights. It will be sublicensable, and any
sublicenses granted by CNRS or Simon
Fraser will be subject to the provisions
of 37 CFR part 401 and 404.
This invention pertains to certain
RNA aptamers with optimized
fluorescent properties and fluorophore
binding affinities as well as
corresponding heterocyclic
fluorophores. The technology consists of
a suite of fluorescent RNA-fluorophore
complexes within the ‘‘Mango’’ that
have been optimized for live-cell
imaging of RNA molecules without
altering biological function, in a manner
analogous to the way that fluorescently
labeled proteins are used to study
specific protein functions within cells.
As such, this technology can be used as
a powerful tool for live-cell study of
RNA function and activity for research
and diagnostic purposes. The
prospective exclusive patent license
will include terms for the sharing of
royalty income with NHLBI from
commercial sublicenses of the patent
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00090
Fmt 4703
Sfmt 4703
rights and may be granted unless within
fifteen (15) days from the date of this
published notice the NHLBI receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license
that are timely filed in response to this
notice will be treated as objections to
the grant of the contemplated exclusive
patent license. In response to this
Notice, the public may file comments or
objections. Comments and objections,
other than those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information from these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5
U.S.C. 552.
Licensing information and copies of
patent applications may be obtained by
emailing Brian W. Bailey, Ph.D.,
bbailey@mail.nih.gov, the indicated
licensing contact at the National Heart,
Lung, and Blood, Office of Technology
Transfer and Development Office of
Technology Transfer, 31 Center Drive,
Room 4A29, MSC2479, Bethesda, MD
20892–2479; telephone: 301–402–5579.
A signed Confidential Disclosure
Agreement may be required to receive
any unpublished information.
Licensing Contact: Brian W. Bailey,
Ph.D.; 301–594–4094; bbailey@
mail.nih.gov.
Bruce D. Goldstein,
Director, Office of Technology Transfer and
Development, National Heart, Lung, and
Blood Institute, National Institutes of Health.
[FR Doc. 2021–04070 Filed 2–26–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
E:\FR\FM\01MRN1.SGM
01MRN1
]]>Agencies
[Federal Register Volume 86, Number 38 (Monday, March 1, 2021)]
[Notices]
[Page 12008]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-04070]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Heart, Lung, and Blood Institute (NHLBI),
National Institutes of Health, Department of Health and Human Services,
is contemplating the grant of sublicensable patent licenses to Simon
Fraser University (``Simon Fraser''), a non-profit university located
in British Columbia, Canada, and Le Centre National de la Recherche
Scientifique (``CNRS''), a public scientific and technological
establishment located in France, its rights to the inventions and
patents listed in the SUPPLEMENTARY INFORMATION section of this notice.
DATES: Only written comments and/or applications for a license which
are received by the NHLBI Office of Technology Transfer and Development
on or before March 16, 2021 will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
and comments relating to the contemplated exclusive patent license
should be directed to: Brian W. Bailey, Ph.D., Senior Technology
Transfer Manager, NHLBI Office of Technology Transfer and Development,
31 Center Drive, Rm. 4A29, MSC 2479, Bethesda, MD 20892-2479 (for
business mail), Telephone (301) 594-4094; Email: [email protected].
SUPPLEMENTARY INFORMATION: The following and all continuing U.S. and
foreign patents/patent applications thereof are the intellectual
properties to be licensed under the prospective agreement to Stanford:
United States Provisional Patent Application No. 62/489,346 filed April
24, 2017 and entitled ``FLUORIGEN-BINDING RNA APTAMERS'' [HHS Reference
No. E-152-2018/0-US-01].
The patent rights in these inventions have been assigned to the
Government of the United States of America, Simon Fraser, and CNRS. The
prospective patent license will be for the purpose of consolidating the
patent rights to CNRS, one of the co-owners of said rights, for
commercial development, and the purpose of consolidating the patent
rights to CNRS and Simon Fraser for marketing. Consolidation of these
co-owned rights is intended to expedite development of the invention,
consistent with the goals of the Bayh-Dole Act codified as 35 U.S.C.
200-212.
The prospective patent license will be worldwide, exclusive, and
may be limited to those fields of use commensurate in scope with the
patent rights. It will be sublicensable, and any sublicenses granted by
CNRS or Simon Fraser will be subject to the provisions of 37 CFR part
401 and 404.
This invention pertains to certain RNA aptamers with optimized
fluorescent properties and fluorophore binding affinities as well as
corresponding heterocyclic fluorophores. The technology consists of a
suite of fluorescent RNA-fluorophore complexes within the ``Mango''
that have been optimized for live-cell imaging of RNA molecules without
altering biological function, in a manner analogous to the way that
fluorescently labeled proteins are used to study specific protein
functions within cells. As such, this technology can be used as a
powerful tool for live-cell study of RNA function and activity for
research and diagnostic purposes. The prospective exclusive patent
license will include terms for the sharing of royalty income with NHLBI
from commercial sublicenses of the patent rights and may be granted
unless within fifteen (15) days from the date of this published notice
the NHLBI receives written evidence and argument that establishes that
the grant of the license would not be consistent with the requirements
of 35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license that are timely filed in
response to this notice will be treated as objections to the grant of
the contemplated exclusive patent license. In response to this Notice,
the public may file comments or objections. Comments and objections,
other than those in the form of a license application, will not be
treated confidentially, and may be made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information from these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Licensing information and copies of patent applications may be
obtained by emailing Brian W. Bailey, Ph.D., [email protected], the
indicated licensing contact at the National Heart, Lung, and Blood,
Office of Technology Transfer and Development Office of Technology
Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda, MD 20892-2479;
telephone: 301-402-5579. A signed Confidential Disclosure Agreement may
be required to receive any unpublished information.
Licensing Contact: Brian W. Bailey, Ph.D.; 301-594-4094;
[email protected].
Bruce D. Goldstein,
Director, Office of Technology Transfer and Development, National
Heart, Lung, and Blood Institute, National Institutes of Health.
[FR Doc. 2021-04070 Filed 2-26-21; 8:45 am]
BILLING CODE 4140-01-P
